BEKHALED, I., Hayet, M., Abdelkrim, B., Hafida, O., Hichem, M., Abdelhammid, D. (2021). Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma. test, 13(2), 37-46. doi: 10.21608/eajbsc.2021.189884
IMENE BEKHALED; Mehida Hayet; Benalia Abdelkrim; Oueldjeriouat Hafida; Mai Abdesselam Hichem; Djebbar Ahmed Abdelhammid. "Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma". test, 13, 2, 2021, 37-46. doi: 10.21608/eajbsc.2021.189884
BEKHALED, I., Hayet, M., Abdelkrim, B., Hafida, O., Hichem, M., Abdelhammid, D. (2021). 'Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma', test, 13(2), pp. 37-46. doi: 10.21608/eajbsc.2021.189884
BEKHALED, I., Hayet, M., Abdelkrim, B., Hafida, O., Hichem, M., Abdelhammid, D. Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma. test, 2021; 13(2): 37-46. doi: 10.21608/eajbsc.2021.189884

Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma

Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology
Article 3, Volume 13, Issue 2, December 2021, Pages 37-46    PDF (1.04 M)
Document Type: Original Article
DOI: 10.21608/eajbsc.2021.189884
Authors
IMENE BEKHALED1; Mehida Hayet2; Benalia Abdelkrim3; Oueldjeriouat Hafida4; Mai Abdesselam Hichem5; Djebbar Ahmed Abdelhammid3
1Biotoxicology Laboratory. Department of Biology. Faculty of Natural and Life Sciences. Djilali Liabès University, Sidi-Bel-Abbès. Algeria.
2Molecular microbiology, proteomics and health Department of Biology. Faculty of Natural and Life Sciences. Djilali Liabès University, Sidi-Bel-Abbès. Algeria
3Environments and Health Research Laboratory. University Djilali Liabes, Sidi-Bel-Abbes, Algeria
4Hematology department EHU Oran Algeria
5Biotoxicology Laboratory. Department of Biology. Faculty of Natural and Life Sciences. Djilali Liabès University, Sidi-Bel-Abbes. Algeria
Abstract
Introduction: Multiple myeloma is a cancer of the plasma cells that attacks and destroys bones. Myeloma is the second most common cancer of the blood and accounts for about 12% of diagnosed hematologic cancers. Depending on the patient's condition and age, the treatment of multiple myeloma aims to eliminate the manifestations of the disease, to contain its progression and/or to treat the complications to ensure a better patient's quality of life. The survival rate in multiple myeloma patients is significantly improved through new therapeutic agents such as monoclonal antibodies, immunomodellers, proteasome inhibitors and hematopoietic stem cells transplantation, which is considered as the standard protocol in patients under 65 years old. The objective of this study is to determine the importance of autologous hematopoietic stem cell transplantation in improving the survival rate and quality of life of patients with multiple myeloma.
Materials and methods: 319 multiple myeloma patients who underwent hematopoietic autologous stem-cell transplantation, were included in this retrospective descriptive and analytical study.
Results: multiple myeloma can affect both sexes, the results of our study revealed a male predominance with a percentage of 61%.
 Dataanalysis shows a significant correlation between the patient's age and the CD 34+ count and a highly significant correlation between cryotherapy and overall survival rate that was about 5 years.
Conclusion: through our study, we have confirmed that autologous transplantation strongly contributes to improving the survival rate of myeloma patients. Hematopoietic stem-cell transplantation remains the first-line treatment for patients under 65 years of age.  
Keywords
Multiple Myeloma; survival rate; hematopoietic stem cells transplantation; cryotherapy
Statistics
Article View: 482
PDF Download: 633